Suppr超能文献

低剂量双氯芬酸钾的生物利用度。

Bioavailability of diclofenac potassium at low doses.

作者信息

Hinz Burkhard, Chevts Julia, Renner Bertold, Wuttke Henrike, Rau Thomas, Schmidt Andreas, Szelenyi Istvan, Brune Kay, Werner Ulrike

机构信息

Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen-Nürnberg, Fahrstrasse 17, D-91054 Erlangen, Germany.

出版信息

Br J Clin Pharmacol. 2005 Jan;59(1):80-4. doi: 10.1111/j.1365-2125.2005.02226.x.

Abstract

AIM

Diclofenac-K has been recently launched at low oral doses in different countries for over-the-counter use. However, given the considerable first-pass metabolism of diclofenac, the degree of absorption of diclofenac-K at low doses remained to be determined. The aim of this study was to determine the bioavailability of low-dose diclofenac-K.

METHODS

A randomized, three-way, cross-over study was performed in 10 subjects. Each received diclofenac-K, 22.5 mg via short-term i.v. infusion and orally at single doses of 12.5 mg and 25 mg.

RESULTS

Mean (+/- SD) times to maximal plasma concentration (t(max)) of diclofenac were 0.48 +/- 0.28 h (12.5 mg) and 0.93 +/- 0.96 h (25 mg). The absolute bioavailability of diclofenac-K after oral administration did not differ significantly in the 12.5-mg and 25-mg dose group (63.1 +/- 12.6%vs. 65.1 +/- 19.4%, respectively). The 90% confidence intervals for the AUC(infinity) and AUC(t) ratios for the two oral regimes were 82.6, 103.4% (point estimate 92.4%) and 86.2, 112.9% (point estimate 98.6%), respectively. These values were within the acceptance criteria for bioequivalence (80-125%).

CONCLUSIONS

Our data indicate that diclofenac-K is rapidly and well absorbed at low dose, and are consistent with a rapid onset of action of the drug. Abbreviations AUC, area under plasma concentration-time curve; C(max), peak plasma concentration; CI, confidence interval; COX, cyclooxygenase; D, dose; F, absolute bioavailability; t(max), time to reach C(max).

摘要

目的

双氯芬酸钾最近已在不同国家以低口服剂量作为非处方药推出。然而,鉴于双氯芬酸显著的首过代谢,低剂量双氯芬酸钾的吸收程度仍有待确定。本研究的目的是测定低剂量双氯芬酸钾的生物利用度。

方法

对10名受试者进行了一项随机、三交叉研究。每位受试者分别接受22.5毫克双氯芬酸钾的短期静脉输注,以及12.5毫克和25毫克的单剂量口服给药。

结果

双氯芬酸的平均(±标准差)达最大血浆浓度时间(t(max))分别为0.48±0.28小时(12.5毫克)和0.93±0.96小时(25毫克)。12.5毫克和25毫克剂量组口服给药后双氯芬酸钾的绝对生物利用度无显著差异(分别为63.1±12.6%和65.1±19.4%)。两种口服给药方案的AUC(∞)和AUC(t)比值的90%置信区间分别为82.6、103.4%(点估计值92.4%)和86.2、112.9%(点估计值98.6%)。这些值在生物等效性的接受标准范围内(80-125%)。

结论

我们的数据表明,双氯芬酸钾在低剂量下吸收迅速且良好,这与该药物起效迅速一致。缩写:AUC,血浆浓度-时间曲线下面积;C(max),血浆峰值浓度;CI,置信区间;COX,环氧化酶;D,剂量;F,绝对生物利用度;t(max),达到C(max)的时间。

相似文献

1
Bioavailability of diclofenac potassium at low doses.
Br J Clin Pharmacol. 2005 Jan;59(1):80-4. doi: 10.1111/j.1365-2125.2005.02226.x.
3
6
Comparative bioavailability of two different diclofenac formulations in healthy volunteers.
Arzneimittelforschung. 1999 Nov;49(11):920-4. doi: 10.1055/s-0031-1300527.
8
Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations.
Arzneimittelforschung. 2011;61(10):566-70. doi: 10.1055/s-0031-1300554.

引用本文的文献

1
Development of lumen-based perfusable 3D liver in vitro model using single-step bioprinting with composite bioinks.
Mater Today Bio. 2023 Jul 8;21:100723. doi: 10.1016/j.mtbio.2023.100723. eCollection 2023 Aug.
4
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
Drug Saf. 2020 Apr;43(4):301-318. doi: 10.1007/s40264-019-00900-8.
6
Rapid absorption of diclofenac and acetaminophen after their oral administration to cattle.
J Vet Med Sci. 2016 Oct 1;78(9):1481-1485. doi: 10.1292/jvms.16-0202. Epub 2016 Jun 18.
9
Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.
Pharm Res. 2009 Apr;26(4):822-35. doi: 10.1007/s11095-008-9781-2. Epub 2008 Dec 12.

本文引用的文献

1
Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac.
Clin Pharmacol Ther. 2003 Sep;74(3):222-35. doi: 10.1016/S0009-9236(03)00167-X.
3
Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt.
Arzneimittelforschung. 2001 Nov;51(11):885-90. doi: 10.1055/s-0031-1300132.
4
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
N Engl J Med. 2001 Dec 20;345(25):1809-17. doi: 10.1056/NEJMoa003199.
6
Onset and duration of analgesia of diclofenac potassium in the treatment of postepisiotomy pain.
Am J Ther. 1997 Jul-Aug;4(7-8):239-46. doi: 10.1097/00045391-199707000-00004.
7
Diclofenac-potassium in migraine: a review.
Drugs. 1999 Jun;57(6):991-1003. doi: 10.2165/00003495-199957060-00016.
8
Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.
Clin Pharmacokinet. 1997 Sep;33(3):184-213. doi: 10.2165/00003088-199733030-00003.
9
Bioequivalence requirements for generic products.
Pharmacol Ther. 1994 Apr-May;62(1-2):41-55. doi: 10.1016/0163-7258(94)90004-3.
10
Dose-dependent disposition of oral propranolol in normal subjects.
Biopharm Drug Dispos. 1980 Apr-Jun;1(4):159-66. doi: 10.1002/bdd.2510010403.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验